Health Care & Life Sciences » Pharmaceuticals | Jiangsu Hengrui Medicine Co. Ltd.

Jiangsu Hengrui Medicine Co. Ltd. A | Cash Flow

Fiscal year is January-December. All values CNY Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
1,292
1,573
2,224
2,634
3,293
4,061
Depreciation, Depletion & Amortization
171
213
222
255
320
381
Other Funds
16
136
19
-
523
336
Funds from Operations
1,473
1,773
2,447
2,855
3,642
4,756
Changes in Working Capital
108
198
169
259
1,044
1,734
Net Operating Cash Flow
1,365
1,574
2,278
2,596
2,597
3,022
Capital Expenditures
453
299
394
1,111
380
Sale of Fixed Assets & Businesses
-
-
1
15
16
Purchase/Sale of Investments
-
-
76
1,543
3,047
Net Investing Cash Flow
453
298
470
2,639
3,411
Cash Dividends Paid - Total
99
122
150
196
317
Issuance/Reduction of Debt, Net
10
10
-
10
-
Net Financing Cash Flow
73
4
132
209
205
Net Change in Cash
840
1,280
1,684
221
651
Free Cash Flow
912
1,276
1,883
1,485
2,217
Deferred Taxes & Investment Tax Credit
-
21
16
19
3
22
Change in Capital Stock
-
-
-
3
1
Exchange Rate Effect
-
-
9
31
42

About Jiangsu Hengrui Medicine Co.

View Profile
Address
No. 7 Kunlunshan Road
Lianyungang Jiangsu 222000
China
Employees -
Website http://www.hrs.com.cn
Updated 07/08/2019
Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. Its products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; psychotropic substances; soft capsules; freeze-dried powder injection; powder injection; high-volume injection including multi-layer co-extruded infusion bag, with anti-tumor drugs; small volume injections including antineoplastic drugs, psychotropic drugs, and non-final sterilization; biological engineering products such as polyethylene glycol recombinant human granulocyte stimulating factor injection; hard capsules; granules; powder; film and gel.